Rituximab in systemic lupus erythematosus and lupus nephritis

Nephron - Clinical Practice

Volumn 128, Issue , 2014, Pages 250-254

  Beckwith, Hannah ^a   Lightstone, Liz ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

B cell depletion therapy; Lupus nephritis; Rituximab; Systemic lupus erythematosus

Indexed keywords

CD20 ANTIGEN; CORTICOSTEROID; MONOCLONAL ANTIBODY; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICATION COMPLIANCE; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID THERAPY; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; RITUXIMAB;

EID: 84922885144     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000368585     Document Type: Review

References (31)

1. Tobon GJ, Izquierdo JH, Canas CA: B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus. Autoimmune Dis 2013, DOI: 10.1155/2013/827254.
2. Pollak VE, Pirani CL, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964; 63:537-550.
3. Croca SC, Rodrigues T, Isenberg DA: Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011; 50: 1424-1430.
4. Ward MM: Changes in the incidence of end-stage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36:63-67.
5. Nikpour M, et al: Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus ery-thematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther 2011; 13:R156.
6. Masood S, Jayne D, Karim Y: Beyond immu-nosuppression-challenges in the clinical management of lupus nephritis. Lupus 2009; 18:106-115.
7. Pepper R, et al: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24:3717-3723.
8. Anolik JH, et al: The relationship of Fcgam-maRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-459.
9. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803-843.
10. Turner-Stokes T, et al: The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011; 50:1401-1408.
11. Edwards JC, et al: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
12. Ferraro AJ, et al: Effective therapeutic use of rituximab in refractory Wegener's granulo-matosis. Nephrol Dial Transplant 2005; 20: 622-625.
13. Patel VL, et al: Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119:5989-5995.
14. Favas C, Isenberg DA: B-cell-depletion therapy in SLE-what are the current prospects for its acceptance? Nat Rev Rheumatol 2009; 5: 711-716.
15. Merrill JT, et al: Efficacy and safety of ritux-imab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus ery-thematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-233.
16. Thanou A, Merrill JT: Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol 2014; 10:23-34.
17. Merrill J, et al: Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20:709-716.
18. Furie R, et al: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930.
19. Navarra SV, et al: Efficacy and safety of beli-mumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-731.
20. van Vollenhoven RF, et al: Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71:1343-1349.
21. Rovin BH, et al: Efficacy and safety of ritux-imab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215-1226.
22. Weening JJ, et al: The classification of glomer-ulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241-250.
23. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-Application to the individual patient. Kidney Int 2012; 82:840-856.
24. Lightstone L: The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 2012; 64: 962-965.
25. Gunnarsson I, Jonsdottir T: Rituximab treatment in lupus nephritis-where do we stand? Lupus 2013; 22:381-389.
26. Lightstone L: Minimising steroids in lupus nephritis-will B cell depletion pave the way? Lupus 2013; 22:390-399.
27. Condon MB, et al: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72:1280-1286.
28. Ezeonyeji AN, Isenberg DA: Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 2012; 51:476-481.
29. Bertsias GK, et al: Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771-1782.
30. Hahn BH, et al: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64:797-808.
31. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Working Group. Kidney Int (Suppl) 2012; 2:221-232.